MTRC has launched a service of cost analysis to support economic modelling or full adaptation of health economics models in Europe

In a new White Paper, MTRC identified evidence requirements for the creation of CCAM codes for diagnostic (non-IVD) procedures performed by physicians based on an analysis of four recent HAS reports with positive and negative recommendations. The analysis was performed in February 2024.

Market access is a rapidly changing field and the landscape varies for different types of medical technologies. To provide an additional, easy-to-access source of high-level information about key themes in the market access landscape and challenges for individual types of medical technologies, MTRC launched a dedicated Knowledge Zone on the website. Currently, the Knowledge Zone includes information about procedure coding, payment mechanisms, policy considerations, HTA, and future challenges for market access for 12 types of medical technologies. In the coming weeks, the Zone will expand 40 key technology groups

In a new White Paper, MTRC identified evidence requirement pitfalls that act as a barrier to listing in the LPPR based on analyzing five recent HAS reports with negative recommendations from different medical disciplines. The analysis was performed in January 2024.

MTRC released several short (2-4 minutes) educational videos on its YouTube channel: “Three common market access barriers for medical technologies”, “Reimbursement models and incentives for healthcare providers”, “How to spot a well-functioning DRG system?” and “Market access challenges for different types of medical technologies”. Videos can be of interest to an audience of both market access professionals and those new to the field of reimbursement, funding, HTA and market access for medical technologies in Europe.

In a new White Paper, MTRC identified evidence requirements for national add-on reimbursement via the LPPR List process based on analysis of five recent HAS reports with positive recommendations. Cases included technologies with different levels of added clinical value (II, III, IV, and V). A review of five cases is followed by recommendations in relation to evidence generation for medical technologies in France, and factors influencing the decision-making of HAS. The analysis was performed in February 2024.